Journey Medical Corporation
DERMHealthcare|Drug Manufacturers - Specialty & Generic|US
$4.47
+0.17 (+3.95%)
Tangible Book / Share
$0.24
Cash / Share
$0.93
Clinical Trials (12)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT02530281 Study of Glycopyrronium in Axillary Hyperhydrosis | Hyperhidrosis | P3 | Completed | 344 | RCT, Double-blind | glycopyrronium Topical Wipes |
| NCT05343455 A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2) | Papulopustular Rosacea | P3 | Completed | 330 | RCT, Double-blind | DFD-29, Doxycycline, Placebo |
| NCT05296629 A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea. | Papulopustular Rosacea | P3 | Completed | 323 | RCT, Double-blind | DFD-29, Doxycycline, Placebo |
| NCT02553798 Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis | Hyperhidrosis | P3 | Completed | 564 | Open-label | Glycopyrronium Topical Wipes |
| NCT02530294 Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis | Hyperhidrosis | P3 | Completed | 353 | RCT, Double-blind | glycopyrronium Topical Wipes |
| NCT03880266 A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis | Palmar Hyperhidrosis | P2 | Completed | 72 | RCT, Double-blind | Glycopyrronium cloth, 2.4%, Vehicle |
| NCT02129660 Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis | Hyperhidrosis | P2 | Completed | 105 | RCT, Double-blind | Dose 1 of glycopyrrolate, 2.0% QD, Dose 2 of glycopyrrolate, 3.0% QD, Dose 1 of glycopyrronium, 2.5% QD, Dose 2 of glycopyrronium, 3.75% QD |
| NCT02016885 A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis | Hyperhidrosis | P2 | Completed | 198 | RCT, Double-blind | glycopyrrolate, 1.0%, glycopyrrolate, 2.0%, glycopyrrolate, 3.0%, glycopyrrolate, 4.0% |
| NCT05597462 Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks | Rosacea | P1 | Completed | 60 | RCT, Double-blind | Minocycline hydrochloride capsules |
| NCT05452785 A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects | Pharmacokinetics | P1 | Completed | 24 | RCT, Open-label | DFD-29 (Minocycline) Fasting, DFD-29 (Minocycline) Fed, Solodyn (Minocycline) Fasting |
| NCT07462702 Topical Minocycline for CARP | Confluent and Reticulated Papillomatosis (CARP) | Early P1 | Not Yet Recruiting | 35 | Single-blind | Topical Minocycline Foam FXFM244 |
| NCT07111429 Chinese Ostomy Collaboration Group (COCG) Clinical Study -SITI Classification | Complication,Postoperative, Stoma | Not Yet Recruiting | 5,000 | — | — |